TY - JOUR
T1 - Genotype-phenotype correlations in chronic granulomatous disease
T2 - insights from a large national cohort
AU - Wolach, Baruch
AU - Gavrieli, Ronit
AU - Wolach, Ofir
AU - Salamon, Pazit
AU - de Boer, Martin
AU - van Leeuwen, Karin
AU - Abuzaitoun, Omar
AU - Broides, Arnon
AU - Gottesman, Giora
AU - Grisaru-Soen, Galia
AU - Hagin, David
AU - Marcus, Nufar
AU - Rottem, Menachem
AU - Schlesinger, Yechiel
AU - Stauber, Tali
AU - Stepensky, Polina
AU - Dinur-Schejter, Yael
AU - Zeeli, Tal
AU - Hanna, Suheir
AU - Etzioni, Amos
AU - Frizinsky, Shirly
AU - Somech, Raz
AU - Roos, Dirk
AU - Lachover-Roth, Idit
N1 - Publisher Copyright:
© 2024 American Society of Hematology
PY - 2024/9/19
Y1 - 2024/9/19
N2 - Neutrophils are the first line of defense against invading pathogens. Neutrophils execute and modulate immune responses by generating reactive oxygen species (ROS). Chronic granulomatous disease (CGD) is a primary immune deficiency disorder of phagocytes, caused by inherited mutations in the genes of the nicotinamide adenine dinucleotide phosphate reduced oxidase enzyme. These mutations lead to failure of ROS generation followed by recurrent bacterial and fungal infections, frequently associated with hyperinflammatory manifestations. We report a multicenter cumulative experience in diagnosing and treating patients with CGD. From 1986 to 2021, 2918 patients experiencing frequent infections were referred for neutrophil evaluation. Among them, 110 patients were diagnosed with CGD: 56 of Jewish ancestry, 48 of Arabic ancestry, and 6 of non-Jewish/non-Arabic ancestry. As opposed to other Western countries, the autosomal recessive (AR) CGD subtypes were predominant in Israel (71/110 patients). Thirty-nine patients had X-linked CGD, in most patients associated with severe infections (clinical severity score ≥3) and poor outcomes, presenting at a significantly earlier age than AR-CGD subtypes. The full spectrum of infections and hyperinflammatory manifestations is described. Six patients had hypomorphic mutations with significantly milder phenotype, clinical severity score ≤2, and better outcomes. Hematopoietic stem cell transplantation was implemented in 39 of 110 patients (35.5%). Successful engraftment was achieved in 92%, with 82% long-term survival and 71% full clinical recovery. CGD is a complex disorder requiring a multiprofessional team. Early identification of the genetic mutation is essential for prompt diagnosis, suitable management, and prevention.
AB - Neutrophils are the first line of defense against invading pathogens. Neutrophils execute and modulate immune responses by generating reactive oxygen species (ROS). Chronic granulomatous disease (CGD) is a primary immune deficiency disorder of phagocytes, caused by inherited mutations in the genes of the nicotinamide adenine dinucleotide phosphate reduced oxidase enzyme. These mutations lead to failure of ROS generation followed by recurrent bacterial and fungal infections, frequently associated with hyperinflammatory manifestations. We report a multicenter cumulative experience in diagnosing and treating patients with CGD. From 1986 to 2021, 2918 patients experiencing frequent infections were referred for neutrophil evaluation. Among them, 110 patients were diagnosed with CGD: 56 of Jewish ancestry, 48 of Arabic ancestry, and 6 of non-Jewish/non-Arabic ancestry. As opposed to other Western countries, the autosomal recessive (AR) CGD subtypes were predominant in Israel (71/110 patients). Thirty-nine patients had X-linked CGD, in most patients associated with severe infections (clinical severity score ≥3) and poor outcomes, presenting at a significantly earlier age than AR-CGD subtypes. The full spectrum of infections and hyperinflammatory manifestations is described. Six patients had hypomorphic mutations with significantly milder phenotype, clinical severity score ≤2, and better outcomes. Hematopoietic stem cell transplantation was implemented in 39 of 110 patients (35.5%). Successful engraftment was achieved in 92%, with 82% long-term survival and 71% full clinical recovery. CGD is a complex disorder requiring a multiprofessional team. Early identification of the genetic mutation is essential for prompt diagnosis, suitable management, and prevention.
UR - http://www.scopus.com/inward/record.url?scp=85200847452&partnerID=8YFLogxK
U2 - 10.1182/blood.2023022590
DO - 10.1182/blood.2023022590
M3 - Article
C2 - 38905634
AN - SCOPUS:85200847452
SN - 0006-4971
VL - 144
SP - 1300
EP - 1313
JO - Blood
JF - Blood
IS - 12
ER -